What is Core Scientific, Inc. Tranche 1 Warrants's earnings per share (EPS)?

Core Scientific, Inc. Tranche 1 Warrants (CORZW) reported diluted earnings per share of -$0.88 for fiscal year 2025. This represents a 81.9% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Core Scientific, Inc. Tranche 1 Warrants (CORZW) Financials

CORZW

Trailing 12 months to June 30, 2026

Revenue $440.3M +26.4% YoY

Net Income -$1.4B -29.2% YoY

EPS (Diluted) -$4.23 -540.9% YoY

Free Cash Flow -$957.7M -273.1% YoY

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Jul 28, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Jul 28, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the CORZW SEC filings page.

Core Scientific, Inc. Tranche 1 Warrants (CORZW) reported $440.3M in revenue over the twelve months to Jun 30, 2026, up 26.4% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI CORZW FY2025 2026-10-04

Core Scientific’s latest figures show a shrinking business whose capital-heavy expansion is not funded by operations.

FY2025 operating cash flow reached $278M while free cash flow was -$451M, showing that cash generated by operations was overwhelmed by reinvestment. Capital expenditures were $729M, so annual expansion was not self-funded by the business’s operating cash generation.

Revenue fell from $511M in FY2024 to $319M in FY2025, while gross margin narrowed from 23.7% to 11.9%. That pairing points to both lower volume and weaker economics per dollar of sales, rather than losses being purely below the gross-profit line.

Balance-sheet leverage is pronounced: liabilities of $3.3B exceeded assets of $2.3B, leaving negative equity and little balance-sheet cushion for continued investment. The current ratio improved to 1.1x from 0.2x in FY2023, but that short-term change does not remove the longer-term solvency pressure implied by negative equity.

Financial Health Signals

Financial Health Score 19/100

Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Core Scientific, Inc. Tranche 1 Warrants's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

Core Scientific, Inc. Tranche 1 Warrants has an operating margin of -77.0%, meaning the company loses $77 on every $100 of revenue. This results in a profitability score of 12/100. This is down from -27.8% the prior year.

Growth

Core Scientific, Inc. Tranche 1 Warrants's revenue declined 37.5% year-over-year, from $510.7M to $319.0M. This contraction results in a growth score of 4/100.

Leverage

Liquidity

Core Scientific, Inc. Tranche 1 Warrants's current ratio of 1.15 is below the typical benchmark, resulting in a score of 26/100. This tight liquidity could limit financial flexibility if cash inflows slow.

Cash Flow

Core Scientific, Inc. Tranche 1 Warrants's reported free cash flow margin for fiscal year 2025 is below the lowest share of revenue this page publishes, so the figure is not shown here. This dimension scores 4/100.

Returns

Piotroski F-Score Partial

3/8

Core Scientific, Inc. Tranche 1 Warrants passes 3 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 3 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.

Earnings Quality Mixed

N/A

Core Scientific, Inc. Tranche 1 Warrants reported a net loss of $288.6M while generating $278.3M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$164.2M

YoY+108.8%

QoQ+42.5%

5Y CAGR+16.9%

Core Scientific, Inc. Tranche 1 Warrants generated $164.2M in revenue in Q2 2026. This represents an increase of 108.8% from the same quarter a year earlier. Against the prior quarter it is up 42.5%.

EBITDA

-$63.1M

YoY-739.4%

QoQ+78.5%

Core Scientific, Inc. Tranche 1 Warrants's EBITDA was -$63.1M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 739.4% from the same quarter a year earlier. Against the prior quarter it is up 78.5%.

Net Income

-$1.2B

YoY-23.3%

QoQ-232.8%

Core Scientific, Inc. Tranche 1 Warrants reported -$1.2B in net income in Q2 2026. This represents a decrease of 23.3% from the same quarter a year earlier. Against the prior quarter it is down 232.8%.

EPS (Diluted)

-$3.32

QoQ-213.2%

Core Scientific, Inc. Tranche 1 Warrants earned -$3.32 per diluted share (EPS) in Q2 2026. Against the prior quarter it is down 213.2%.

Cash & Balance Sheet

Free Cash Flow

-$583.9M

YoY-569.1%

QoQ-319.1%

Core Scientific, Inc. Tranche 1 Warrants recorded an outflow of $583.9M in free cash flow in Q2 2026, representing a cash shortfall after capex. This represents a decrease of 569.1% from the same quarter a year earlier. Against the prior quarter it is down 319.1%.

Cash & Debt

$1.8B

YoY+204.4%

QoQ+76.1%

5Y CAGR+286.8%

Core Scientific, Inc. Tranche 1 Warrants held $1.8B in cash against $4.3B in long-term debt as of Q2 2026.

Shares Outstanding

321M

QoQ+1.1%

Core Scientific, Inc. Tranche 1 Warrants had 321M shares outstanding in Q2 2026. Against the prior quarter it is up 1.1%.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Gross Margin

42.7%

YoY+36.3pp

QoQ+16.5pp

5Y change+10.1pp

Core Scientific, Inc. Tranche 1 Warrants's gross margin was 42.7% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is up 36.3 percentage points from the same quarter a year earlier. Against the prior quarter it is up 16.5 percentage points.

Operating Margin

-47.8%

YoY-14.4pp

5Y change-68.4pp

Core Scientific, Inc. Tranche 1 Warrants's operating margin was -47.8% in Q2 2026, reflecting core business profitability. This is down 14.4 percentage points from the same quarter a year earlier.

Net Margin

Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Return on Equity

Not reported for Q2 2026.

Capital Allocation

Capital Expenditures

$565.0M

YoY+365.9%

QoQ+45.2%

5Y CAGR+82.0%

Core Scientific, Inc. Tranche 1 Warrants invested $565.0M in capex in Q2 2026, funding long-term assets and infrastructure. This represents an increase of 365.9% from the same quarter a year earlier. Against the prior quarter it is up 45.2%.

R&D Spending

Not reported for Q2 2026.

Share Buybacks

Not reported for Q2 2026.

CORZW Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

CORZW quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K
Revenue	$440.3M	$319.0M-37.5%	$510.7M+1.6%	$502.4M-21.5%	$640.3M+17.6%	$544.5M	N/A
Cost of Revenue	$315.5M	$281.1M-27.8%	$389.6M+2.8%	$378.9M-40.0%	$631.9M+106.8%	$305.6M	N/A
Gross Profit	$124.8M	$37.9M-68.7%	$121.1M-1.9%	$123.5M+1369.8%	$8.4M-96.5%	$238.9M	N/A
R&D Expenses	N/A	N/A	$11.8M+64.7%	$7.2M-73.4%	$27.0M+251.3%	$7.7M	N/A
SG&A Expenses	$175.9M	$159.2M+40.0%	$113.7M+5.2%	$108.1M-49.3%	$213.3M+252.6%	$60.5M	N/A
Operating Income	-$561.2M	-$245.6M-72.9%	-$142.1M-1685.4%	$9.0M+100.4%	-$2.1B-1704.3%	$131.5M	N/A
EBITDA	N/A	-$176.7M-512.2%	-$28.9M-127.5%	$105.0M+105.6%	-$1.9B-1243.0%	$164.9M	N/A
Interest Expense	N/A	N/A	$37.1M-57.0%	$86.2M-10.9%	$96.8M+118.3%	$44.4M	N/A
Income Tax	$2.7M	$583K-32.1%	$859K+25.8%	$683K+104.0%	-$17.1M-208.4%	$15.8M	$0
Net Income	-$1.4B	-$288.6M+79.9%	-$1.4B-483.3%	-$246.5M+88.5%	-$2.1B-4636.5%	$47.3M	N/A
EPS (Basic)	N/A	-$0.88+81.9%	-$4.87-649.2%	-$0.65+89.7%	-$6.30-2839.1%	$0.23+264.3%	-$0.14
EPS (Diluted)	-$4.23	-$0.88+81.9%	-$4.87-649.2%	-$0.65	-$6.30-3250.0%	$0.20+242.9%	-$0.14
Diluted Shares (Avg)	N/A	318M+24.3%	256M-32.7%	380M	341M+46.0%	233M+48.0%	158M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Revenue	$164.2M+108.8%	$115.2M+44.9%	$79.8M-16.0%	$81.1M-14.9%	$78.6M-44.3%	$79.5M-55.6%	$94.9M-33.1%	$95.4M-15.5%
Cost of Revenue	$94.2M+27.9%	$85.1M+19.4%	$59.0M-34.6%	$77.2M-19.2%	$73.6M-28.0%	$71.3M-29.8%	$90.2M-12.1%	$95.5M-2.0%
Gross Profit	$70.0M+1293.9%	$30.1M+266.6%	$20.8M+335.8%	$3.9M+2603.2%	$5.0M-87.1%	$8.2M-89.4%	$4.8M-87.9%	-$156K-101.0%
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A	$5.0M+167.4%	$2.8M+26.1%
SG&A Expenses	$49.4M+9.1%	$44.8M+38.9%	$12.3M-50.9%	$69.4M+71.9%	$45.3M+44.3%	$32.3M+90.8%	$25.0M-34.9%	$40.3M+71.6%
Operating Income	-$78.5M-198.5%	-$310.4M-559.9%	-$117.5M-79.7%	-$54.8M-32.9%	-$26.3M+71.0%	-$47.0M-185.2%	-$65.4M-1762.2%	-$41.2M-242.2%
EBITDA	-$63.1M-739.4%	-$293.8M-975.8%	-$103.4M-162.7%	-$38.5M-207.0%	-$7.5M+87.7%	-$27.3M-132.4%	-$39.4M-212.0%	-$12.5M-202.8%
Interest Expense	$40.6M+755.0%	$8.2M+71.9%	N/A	N/A	$4.8M-67.8%	$4.7M-66.3%	$1.1M	$7.1M+222.0%
Income Tax	$1.9M+1107.0%	$600K+192.7%	$95K-74.7%	$125K-6.7%	$158K+9.7%	$205K-0.5%	$375K+11.6%	$134K+17.5%
Net Income	-$1.2B-23.3%	-$347.2M-160.2%	$216.0M+174.2%	-$144.0M+68.4%	-$936.8M-3.8%	$576.3M+173.5%	-$291.1M-48.8%	-$455.3M-1006.4%
EPS (Basic)	-$3.32-8200.0%	-$1.06-174.6%	$0.60+187.0%	-$0.45+61.5%	-$0.04+99.2%	$1.42+56.0%	-$0.69-32.7%	-$1.17-963.6%
EPS (Diluted)	-$3.32	-$1.06-185.5%	$0.60+187.0%	-$0.45+61.5%	-$0.04	$1.24	-$0.69-32.7%	-$1.17-963.6%
Diluted Shares (Avg)	325M	323M-11.1%	N/A	319M+8.9%	318M	363M	N/A	292M-23.5%

CORZW Balance Sheet

CORZW quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K
Total Assets	$2.3B+59.1%	$1.5B+107.3%	$712.2M-11.8%	$807.7M-66.9%	$2.4B+16258993.3%	$15K
Current Assets	$895.5M-0.9%	$904.0M+831.8%	$97.0M+14.0%	$85.1M-88.8%	$756.6M	N/A
Cash & Equivalents	$311.4M-62.8%	$836.2M+1558.8%	$50.4M+217.4%	$15.9M-86.5%	$117.9M	N/A
Short-Term Investments	$0	$0	$0	$0	$0	N/A
Accounts Receivable	N/A	$1.0M+2.4%	$1.0M+327.8%	$234K-83.1%	$1.4M	N/A
Long-Term Investments	$0	$0	$0	$0	$0	N/A
Goodwill	N/A	N/A	$0	$0-100.0%	$1.1B	N/A
Total Liabilities	$3.3B+36.8%	$2.4B+84.8%	$1.3B+7.6%	$1.2B+15.6%	$1.1B+1280.6%	-$89.2M
Current Liabilities	$781.4M+480.7%	$134.6M-72.4%	$488.4M+161.5%	$186.8M-41.7%	$320.3M+80072150.0%	$400
Non-Current Liabilities	$2.5B+10.7%	$2.3B+178.4%	$820.7M-20.3%	$1.0B+40.6%	$732.9M+921.5%	-$89.2M
Long-Term Debt	$1.1B	N/A	N/A	N/A	N/A	N/A
Total Equity	-$962.7M-2.1%	-$943.0M-58.0%	-$596.9M-45.8%	-$409.3M-130.5%	$1.3B+1403.2%	$89.2M
Retained Earnings	-$4.1B-7.5%	-$3.9B-59.4%	-$2.4B-11.3%	-$2.2B-7824.1%	-$27.4M-263669.2%	-$10K

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$5.3B+184.1%	$3.1B+104.9%	$2.3B+59.1%	$2.2B+163.3%	$1.9B+178.6%	$1.5B+84.0%	$1.5B+107.3%	$824.6M+16.9%
Current Assets	$2.4B+143.2%	$1.5B+74.6%	$895.5M-0.9%	$1.1B+281.9%	$1.0B+752.5%	$833.2M+481.3%	$904.0M+831.8%	$277.9M+106.2%
Cash & Equivalents	$1.8B+204.4%	$1.0B+44.0%	$311.4M-62.8%	$453.4M+79.2%	$581.3M+504.8%	$697.9M+611.3%	$836.2M+1558.8%	$253.0M+500.3%
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	$1.0M-8.0%	$1.0M+2.4%	$6.2M
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$7.7B+152.3%	$4.4B+142.1%	$3.3B+36.8%	$3.4B+107.4%	$3.0B+64.9%	$1.8B+59.6%	$2.4B+84.8%	$1.7B+46.9%
Current Liabilities	$2.7B+386.5%	$2.7B+1261.5%	$781.4M+480.7%	$669.9M+775.5%	$562.7M+652.1%	$195.5M+41.5%	$134.6M-72.4%	$76.5M-75.5%
Non-Current Liabilities	$4.9B+99.2%	$1.7B+6.3%	$2.5B+10.7%	$2.8B+74.9%	$2.5B+40.1%	$1.6B+62.1%	$2.3B+178.4%	$1.6B+94.0%
Long-Term Debt	$4.3B	$1.1B	$1.1B	N/A	N/A	N/A	N/A	N/A
Total Equity	-$2.4B-103.0%	-$1.3B-322.8%	-$962.7M-2.1%	-$1.3B-51.5%	-$1.2B-0.9%	-$308.8M+3.0%	-$943.0M-58.0%	-$826.7M-97.4%
Retained Earnings	-$5.6B-33.9%	-$4.5B-36.9%	-$4.1B-7.5%	-$4.4B-22.3%	-$4.2B-35.6%	-$3.3B-48.5%	-$3.9B-59.4%	-$3.6B-60.3%

Not reported in any period shown, so not listed: Inventory, Goodwill.

CORZW Cash Flow Statement

CORZW quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K
Operating Cash Flow	$520.2M	$278.3M+548.7%	$42.9M-34.1%	$65.1M-68.3%	$205.2M+461.7%	-$56.7M	N/A
Depreciation & Amortization	N/A	$68.9M-39.1%	$113.2M+17.9%	$96.0M-57.4%	$225.3M+575.2%	$33.4M	N/A
Stock-Based Compensation	N/A	$98.2M+89.2%	$51.9M-11.8%	$58.9M-67.8%	$182.9M+369.7%	$38.9M+1182.1%	$3.0M
Capital Expenditures	$1.5B	$729.0M+667.7%	$95.0M+487.6%	$16.2M-95.8%	$384.0M	$0	$0
Free Cash Flow	-$957.7M	-$450.8M-765.7%	-$52.1M-206.4%	$49.0M+127.4%	-$178.8M-215.1%	-$56.7M	N/A
Investing Cash Flow	-$1.7B	-$740.8M-678.2%	-$95.2M-3077.3%	-$3.0M+99.5%	-$590.8M-39.4%	-$423.8M	N/A
Financing Cash Flow	$3.2B	-$63.1M-107.7%	$819.6M+1935.6%	-$44.6M-114.6%	$306.2M-49.3%	$603.5M	N/A
Share Buybacks	N/A	N/A	$0	$0-100.0%	$31.6M	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	-$18.9M-155.7%	$249.9M+654.8%	$157.5M+1041.0%	$131.8M+2206.7%	$34.0M+2723.9%	-$45.0M-303.1%	$13.8M-36.4%	$5.7M+5.1%
Depreciation & Amortization	$15.4M-18.0%	$16.6M-15.6%	$14.1M-45.9%	$16.3M-43.1%	$18.8M-36.3%	$19.7M-32.0%	$26.0M-16.5%	$28.7M+18.4%
Stock-Based Compensation	$18.2M-24.5%	$17.8M+9.7%	N/A	$29.9M+47.6%	$24.2M+184.6%	$16.2M+1626.9%	N/A	$20.3M+36.5%
Capital Expenditures	$565.0M+365.9%	$389.2M+363.5%	$279.2M+871.0%	$244.5M+684.3%	$121.3M+3768.5%	$84.0M+163.3%	$28.8M+147.0%	$31.2M+1036.9%
Free Cash Flow	-$583.9M-569.1%	-$139.3M-8.0%	-$121.7M-714.1%	-$112.7M-342.7%	-$87.3M-4419.9%	-$129.0M-1227.4%	-$15.0M-248.7%	-$25.5M-1045.8%
Investing Cash Flow	-$796.2M-565.7%	-$386.7M-334.4%	-$277.8M-864.5%	-$254.4M-714.2%	-$119.6M-3656.5%	-$89.0M-178.4%	-$28.8M-1320.3%	-$31.2M-989.3%
Financing Cash Flow	$2.2B+7089.1%	$971.4M+23239.2%	-$21.8M-103.6%	-$5.3M-102.9%	-$31.8M-109.2%	-$4.2M-107.7%	$598.2M+3369.2%	$182.2M+1284.6%

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

CORZW Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

CORZW quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K
Gross Margin	11.9%-11.8pp	23.7%-0.9pp	24.6%+23.3pp	1.3%-42.6pp	43.9%	N/A
Operating Margin	-77.0%-49.2pp	-27.8%-29.6pp	1.8%	-329.5%	24.1%	N/A
Net Margin	-90.5%	-281.6%	-49.1%	-335.2%	8.7%	N/A
Return on Equity	N/A	N/A	N/A	N/A	3.5%	N/A
Return on Assets	-12.3%+85.1pp	-97.4%-62.8pp	-34.6%+231.1pp	-265.7%-267.7pp	1.9%	N/A
Current Ratio	1.15-5.6x	6.72+6.5x	0.20-0.3x	0.46-1.9x	2.36	N/A
Debt-to-Equity	N/A	N/A	N/A	N/A	0.79	N/A
Asset Turnover	0.14-0.2x	0.35-0.4x	0.71-0.1x	0.79+0.6x	0.22	N/A
FCF Margin	-141.3%	-10.2%-19.9pp	9.7%+37.7pp	-27.9%-17.5pp	-10.4%	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Gross Margin	42.7%+36.3pp	26.1%+15.8pp	26.0%+21.0pp	4.8%+5.0pp	6.4%-21.1pp	10.3%-33.0pp	5.0%-22.7pp	-0.2%-13.8pp
Operating Margin	-47.8%-14.4pp	-269.4%	-147.3%	-67.6%-24.3pp	-33.4%+30.8pp	-59.2%-90.0pp	-68.9%-71.7pp	-43.2%-32.6pp
Net Margin	-703.6%	-301.3%	270.8%	-177.6%	-1191.4%	724.6%	-306.7%	-477.4%
Return on Assets	-22.0%+28.6pp	-11.3%-49.8pp	9.2%+28.9pp	-6.6%+48.6pp	-50.6%+85.2pp	38.5%+12.6pp	-19.7%+7.7pp	-55.2%-49.4pp
Current Ratio	0.89-0.9x	0.55-3.7x	1.15-5.6x	1.58-2.0x	1.79+0.2x	4.26+3.2x	6.72+6.5x	3.63+3.2x
Asset Turnover	0.030.0x	0.040.0x	0.030.0x	0.04-0.1x	0.04-0.2x	0.05-0.2x	0.06-0.1x	0.120.0x
FCF Margin	-355.6%	-120.9%	-152.6%	-139.0%	-111.0%	-162.2%	-15.8%-22.8pp	-26.7%-29.1pp

Not reported in any period shown, so not listed: Return on Equity, Debt-to-Equity.

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.

Note: Shareholder equity is negative (-$962.7M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Core Scientific, Inc. Tranche 1 Warrants CORZW	FY2025	$319.0M	-$288.6M	-90.5%	N/A	19/100
Core Scientific, Inc. Tranche 2 Warrants CORZZ	FY2025	$319.0M	-$288.6M	-90.5%	N/A	19/100
Strategy Inc Variable Rate Series A Perpetual Stretch Preferred Stock STRC	FY2025	$477.2M	-$3.8B	N/A	N/A	40/100
XBP Europe Holdings, Inc. Warrant XBPEW	FY2024	$872.7M	-$215.2M	-24.6%	N/A	13/100
APPTECH PAYMENTS CORP WTS APCXW	FY2025	$1.4M	-$7.9M	N/A	N/A	41/100

Where Core Scientific, Inc. Tranche 1 Warrants Ranks

Frequently Asked Questions

What is Core Scientific, Inc. Tranche 1 Warrants's annual revenue?

Core Scientific, Inc. Tranche 1 Warrants (CORZW) reported $319.0M in total revenue for fiscal year 2025. This represents a -37.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Core Scientific, Inc. Tranche 1 Warrants's revenue growing?

Core Scientific, Inc. Tranche 1 Warrants (CORZW) revenue declined by 37.5% year-over-year, from $510.7M to $319.0M in fiscal year 2025.

Is Core Scientific, Inc. Tranche 1 Warrants profitable?

No, Core Scientific, Inc. Tranche 1 Warrants (CORZW) reported a net income of -$288.6M in fiscal year 2025, with a net profit margin of -90.5%.

What is Core Scientific, Inc. Tranche 1 Warrants's EBITDA?

Core Scientific, Inc. Tranche 1 Warrants (CORZW) had EBITDA of -$176.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Core Scientific, Inc. Tranche 1 Warrants have?

As of fiscal year 2025, Core Scientific, Inc. Tranche 1 Warrants (CORZW) had $311.4M in cash and equivalents against $1.1B in long-term debt.

What is Core Scientific, Inc. Tranche 1 Warrants's gross margin?

Core Scientific, Inc. Tranche 1 Warrants (CORZW) had a gross margin of 11.9% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Core Scientific, Inc. Tranche 1 Warrants's operating margin?

Core Scientific, Inc. Tranche 1 Warrants (CORZW) had an operating margin of -77.0% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Core Scientific, Inc. Tranche 1 Warrants's net profit margin?

Core Scientific, Inc. Tranche 1 Warrants (CORZW) had a net profit margin of -90.5% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Core Scientific, Inc. Tranche 1 Warrants's free cash flow?

Core Scientific, Inc. Tranche 1 Warrants (CORZW) recorded an outflow of $450.8M in free cash flow during fiscal year 2025. This represents a -765.7% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Core Scientific, Inc. Tranche 1 Warrants's operating cash flow?

Core Scientific, Inc. Tranche 1 Warrants (CORZW) generated $278.3M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Core Scientific, Inc. Tranche 1 Warrants's total assets?

Core Scientific, Inc. Tranche 1 Warrants (CORZW) had $2.3B in total assets as of fiscal year 2025, including both current and long-term assets.

What are Core Scientific, Inc. Tranche 1 Warrants's capital expenditures?

Core Scientific, Inc. Tranche 1 Warrants (CORZW) invested $729.0M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How many shares does Core Scientific, Inc. Tranche 1 Warrants have outstanding?

Core Scientific, Inc. Tranche 1 Warrants (CORZW) had 315M shares outstanding as of fiscal year 2025.

What is Core Scientific, Inc. Tranche 1 Warrants's current ratio?

Core Scientific, Inc. Tranche 1 Warrants (CORZW) had a current ratio of 1.15 as of fiscal year 2025, which is considered adequate.

What is Core Scientific, Inc. Tranche 1 Warrants's return on assets (ROA)?

Core Scientific, Inc. Tranche 1 Warrants (CORZW) had a return on assets of -12.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Why is Core Scientific, Inc. Tranche 1 Warrants's debt-to-equity ratio negative or not reported?

Core Scientific, Inc. Tranche 1 Warrants (CORZW) has negative shareholder equity of -$962.7M as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

What is Core Scientific, Inc. Tranche 1 Warrants's Piotroski F-Score?

Core Scientific, Inc. Tranche 1 Warrants (CORZW) has a Piotroski F-Score of 3 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Core Scientific, Inc. Tranche 1 Warrants's earnings high quality?

Core Scientific, Inc. Tranche 1 Warrants (CORZW) reported a net loss of $288.6M while generating $278.3M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Core Scientific, Inc. Tranche 1 Warrants?

Core Scientific, Inc. Tranche 1 Warrants (CORZW) scores 19 out of 100 on our Financial Health Score, indicating weak standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.